Cogent Biosciences, Inc. COGT Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $312.01M+218% | $98.17M+84.4% | $53.23M-61.9% | $139.89M-36.3% | ||
| $588.75M+212% | $188.91M-11.1% | $212.48M+78.0% | $119.39M— | ||
| $416K— | $0— | $0-100% | $1.26M0.0% | ||
| $9.59M+2.1% | $9.4M+85.6% | $5.06M+14.1% | $4.44M+50.4% | ||
| $910.36M+207% | $296.47M+9.5% | $270.77M+2.2% | $264.97M+19.0% | ||
| $5.46M-15.6% | $6.47M-22.5% | $8.34M+7.2% | $7.78M+356% | ||
| $18.08M-10.0% | $20.1M-8.6% | $22M-5.7% | $23.32M+741% | ||
| $3.3M-32.1% | $4.86M0.0% | $4.86M+2.5% | $4.75M+27.3% | ||
| $937.61M+186% | $327.9M+4.6% | $313.44M+4.2% | $300.81M+29.6% | ||
| $9.5M-20.9% | $12.01M+12.7% | $10.66M+82.4% | $5.84M+67.7% | ||
| $1.55M-1.2% | $1.57M+12.9% | $1.39M-2.6% | $1.42M-38.8% | ||
| $63.95M+14.8% | $55.71M+46.0% | $38.17M+42.2% | $26.85M+57.2% | ||
| $14.36M-9.7% | $15.9M-9.0% | $17.47M-4.2% | $18.23M+2,093% | ||
| $33K— | $0— | —— | —— | ||
| $301.24M+321% | $71.61M+28.7% | $55.64M+23.4% | $45.08M+152% | ||
| $161K+46.4% | $110K+27.9% | $86K+22.9% | $70K+59.1% | ||
| $1.73B+72.7% | $1B+25.4% | $801.06M+33.3% | $601.15M+50.4% | ||
| -$1.19B-38.3% | -$859.48M-42.4% | -$603.62M-46.8% | -$411.21M-51.8% | ||
| $355K-20.6% | $447K+81.7% | $246K+337% | -$104K— | ||
| $636.37M+148% | $256.29M-0.6% | $257.8M+0.8% | $255.74M+19.4% | ||
| $937.61M+186% | $327.9M+4.6% | $313.44M+4.2% | $300.81M+29.6% | ||
| $588.75M+212% | $188.91M-11.1% | $212.48M+78.0% | $119.39M— | ||
| $3.3M-32.1% | $4.86M0.0% | $4.86M+2.5% | $4.75M+27.3% | ||
| $18.08M-10.0% | $20.1M-8.6% | $22M-5.7% | $23.32M+741% | ||
| $18.08M-10.0% | $20.1M-8.6% | $22M-5.7% | $23.32M+741% | ||
| $3.3M-32.1% | $4.86M0.0% | $4.86M+2.5% | $4.75M+27.3% | ||
| $18.08M-10.0% | $20.1M-8.6% | $22M-5.7% | $23.32M+741% | ||
| $3.3M-32.1% | $4.86M0.0% | $4.86M+2.5% | $4.75M+27.3% | ||
| $52.9M+25.6% | $42.13M+61.3% | $26.13M+46.1% | $17.88M+118% | ||
| $222.9M— | $0— | —— | —— | ||
| $15.9M-9.0% | $17.47M-7.4% | $18.85M-4.1% | $19.65M+523% | ||
| $1.73B+72.7% | $1B+25.4% | $801.06M+33.3% | $601.15M+50.4% | ||
| $161K+46.4% | $110K+27.9% | $86K+22.9% | $70K+59.1% | ||
| $222.9M— | $0— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cogent Biosciences, Inc.'s total assets?
- Cogent Biosciences, Inc. (COGT) holds $903.0M in total assets, up 218.2% year over year.
- How much debt does Cogent Biosciences, Inc. have?
- Cogent Biosciences, Inc. carries $15.5M in total debt against $607.7M of shareholders' equity, a debt-to-equity ratio of 0.03.
- How much cash does Cogent Biosciences, Inc. have?
- Cogent Biosciences, Inc. holds $241.2M in cash and equivalents.
- Can Cogent Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 15.14 — current assets exceed current liabilities.
- Where does Cogent Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
